DKDaisuke Kato

Daisuke Kato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daisuke Kato has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4)

    by Yoshiya Tanaka, Tsutomu Takeuchi, Yoshiaki Morita, Daisuke Kato, Yuichiro Kaneko, Wataru Terada

    Evaluation of remission rates and their relationship with baseline characteristics in patients with rheumatoid arthritis (RA) treated with the oral Janus kinase (JAK) inhibitor peficitinib. This post hoc analysis of data from two phase 3 studies (RAJ3, RAJ4) of peficitinib (100 mg/day, 150 mg/day) in Asian RA patients investigated clinical disease activity index (CDAI) remission and low disease activity (LDA) rates from baseline to week 52. CDAI, Health Assessment Questionnaire–Disability Index (HAQ-DI), and van der Heijde-modified total Sharp score (mTSS) remission/LDA rates at week 52 were evaluated among patients achieving CDAI remission at weeks 12/28. Logistic regression analyses explored the relationship between baseline characteristics and CDAI remission/LDA rates. CDAI remission rates increased over time in a dose-dependent fashion in both peficitinib-treated groups. Most patients achieving CDAI remission at weeks 12/28 also achieved remission at week 52. Following multivariate analysis of demographic and baseline characteristics, factors associated with achievement of CDAI remission at week 28 included male sex, low baseline prednisone dose (RAJ3 only), and low baseline DAS28-CRP (RAJ4 only). Peficitinib demonstrated persistent efficacy in clinical remission to week 52. Baseline characteristics associated with CDAI remission were mostly consistent with previous studies using other DMARDs.


  • Open Access

    A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan

    by Yuko Kaneko, Masaya Sakurai, Robert Snijder, Satoshi Kokubo, Daisuke Kato

    Objectives: There is limited information on the clinical use of Janus kinase inhibitors (JAKis) for rheumatoid arthritis treatment in Japan. The aim of this study was to identify disease-modifying antirheumatic drug (DMARD) treatment patterns in Japan. Methods: This retrospective, longitudinal study extracted data from the Japan Medical Data Center database. Patients with rheumatoid arthritis diagnosis were enrolled 2016–19, during which patients had a first prescription of a major DMARD, split into six mutually exclusive classes: methotrexate (MTX); other conventional synthetic DMARDs; tumour necrosis factor alpha inhibitors; cytotoxic T-lymphocyte-associated antigen-4-immunoglobulin; anti-interleukin-6 receptor therapies; and JAKis. The primary objective was to describe DMARD treatment patterns, especially for JAKis. Results: Overall, 10,399 patients were included in the analysis. The most common treatments were MTX, other conventional synthetic DMARDs, and tumour necrosis factor alpha inhibitors. The total number of JAKi prescriptions increased approximately 8-fold during 2016–19. Most (61.1%) patients who received JAKis had prior MTX or tumour necrosis factor alpha inhibitor treatment. The duration of JAKi treatment was longer than for biologics and other conventional synthetic DMARDs and comparable to that of MTX. Conclusions: The sequence of drug class prescriptions for rheumatoid arthritis in Japan during 2016–19 followed clinical guidelines. Over this period, JAKis were increasingly used as a second-line treatment following MTX.


  • Open Access

    A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years

    by Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda

    To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). This was a post hoc analysis of pooled data from one Phase 2b study and two Phase 3 studies and final data from a long-term extension study of peficitinib in Asian rheumatoid arthritis patients. Two pooled datasets were analysed (Phase 3 studies and Phase 2/3 studies). Univariate and multivariate Cox regression analyses explored relationships between exposure-adjusted incidence rate of SI and HZD, peficitinib dose, and baseline factors. Total peficitinib exposure for 1052 patients receiving once-daily peficitinib in the pooled Phase 2/3 Asian studies was 2998.9 patient-years. Exposure-adjusted incidence rates (95% confidence interval) of SI and HZD were 2.7 (2.2, 3.4) and 6.9 (6.0, 8.0) per 100 patient-years, respectively, in pooled Phase 2/3 studies. Advanced age was prognostic for SI and HZD, while baseline prednisolone dose was prognostic for SI. There was no temporal relationship between either adverse event and prolonged peficitinib administration. As expected in this peficitinib-treated population, older patients had increased risk of SI and HZD, and those receiving higher prednisolone doses had increased risk of SI.


  • Open Access

    Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis

    by Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Daisuke Miyatake

    Objectives: To evaluate peficitinib efficacy and safety in Asian patients with rheumatoid arthritis (RA), stratified by age (≥20–<50, ≥50–<65, and ≥65 years). Methods: Efficacy data from two Phase 3 studies were analysed. Safety data from one Phase 2, two Phase 3, and one open-label extension study were pooled. Incidence rates per 100 patient-years of adverse events of special interest were calculated, and Cox proportional hazard analysis was conducted. Results: 1052 patients received peficitinib for 2 years (median). Peficitinib demonstrated efficacy improvements versus placebo across all age categories. Incidence rates (95% confidence interval) per 100 patient-years for ≥20–<50, ≥50–<65, and ≥65 years were 0.8 (0.4, 1.9), 2.6 (1.8, 3.7), and 4.7 (3.1, 7.0) for serious infections and 3.7 (2.5, 5.4), 6.4 (5.0, 8.2), and 11.2 (8.5, 14.7) for herpes zoster–related disease, respectively. Twenty patients reported malignancies in pooled Phase 2/3 studies. Incidences of serious infections and herpes zoster–related disease increased significantly with age, but there was no association with baseline estimated glomerular filtration rate. Conclusions: Peficitinib was efficacious in adult Asian RA patients of all ages. Age, but not estimated glomerular filtration rate, was associated with serious infections and herpes zoster–related disease, demonstrating the importance of an appropriate RA treatment strategy in older patients.


  • Open Access

    Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy

    by Takao Katoh, Hidehiro Kakizaki, Kyu‐Sung Lee, Kota Ishida, Daisuke Katou, Osamu Yamamoto, Jar Jar Jong, Budiwan Sumarsono, Satoshi Uno, Osamu Yamaguchi

    Objectives To investigate the cardiovascular safety of mirabegron add-on treatment to tamsulosin in male patients with residual overactive bladder symptoms. Methods This was a post hoc analysis of MATCH, the first double-blind, placebo-controlled study comparing mirabegron and placebo as add-on therapy to tamsulosin for treatment of overactive bladder in men with lower urinary tract symptoms. The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up. Results Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group). Hypertension (two patients) and increased blood pressure (one patient) were reported in the tamsulosin + placebo group, but there were no blood pressure-related treatment-emergent adverse events among tamsulosin + mirabegron patients. There were no clinically meaningful changes from baseline in blood pressure, and changes in pulse rate were small (+1.2 bpm in the tamsulosin + mirabegron group). Increased pulse rate was more frequent with tamsulosin + mirabegron than with tamsulosin + placebo in older patients, although within the normal range. Conclusions Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.


  • Open Access

    A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years

    by Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, Hiroyuki Izutsu, Yuichiro Kaneko, Musashi Fukuda, Daisuke Kato

    To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [dat...


  • Open Access

    Contents of Polyamines in ISHIRU (Fish Sauce)

    by Toshihide Michihata, Daisuke Kato, Toshihiro Yano, Toshiki Enomoto